Literature DB >> 28638299

Cannabinoids in Pediatrics.

Christopher T Campbell, Marjorie Shaw Phillips, Kalen Manasco.   

Abstract

Despite its controversial nature, the use of medical marijuana and cannabis-derived medicinal products grows more popular with each passing year. As of November 2016, over 40 states have passed legislation regarding the use of either medical marijuana or cannabidiol products. Many providers have started encountering patients experimenting with cannabis products for a wide range of conditions. While the debate continues regarding these agents for both medicinal and recreational use in the general population, special consideration needs to be made for pediatric use. This review will deliver the history of marijuana use and legislation in the United States in addition to the currently available medical literature to equip pediatric health care providers with resources to provide patients and their parents the best recommendation for safe and appropriate use of cannabis-containing compounds.

Entities:  

Keywords:  CBD, cannabidiol; cannabis; epilepsy; pediatrics; pharmacy

Year:  2017        PMID: 28638299      PMCID: PMC5473390          DOI: 10.5863/1551-6776-22.3.176

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  27 in total

1.  Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.

Authors:  Shaun A Hussain; Raymond Zhou; Catherine Jacobson; Julius Weng; Emily Cheng; Johnson Lay; Phoebe Hung; Jason T Lerner; Raman Sankar
Journal:  Epilepsy Behav       Date:  2015-04-29       Impact factor: 2.937

2.  The case for medical marijuana in epilepsy.

Authors:  Edward Maa; Paige Figi
Journal:  Epilepsia       Date:  2014-05-22       Impact factor: 5.864

3.  Legal marijuana and pediatric exposure pot edibles implicated in spike in child emergency department visits.

Authors:  Eric Berger
Journal:  Ann Emerg Med       Date:  2014-10       Impact factor: 5.721

4.  Persistent cannabis users show neuropsychological decline from childhood to midlife.

Authors:  Madeline H Meier; Avshalom Caspi; Antony Ambler; HonaLee Harrington; Renate Houts; Richard S E Keefe; Kay McDonald; Aimee Ward; Richie Poulton; Terrie E Moffitt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205

Review 5.  Medical marijuana: review of the science and implications for developmental-behavioral pediatric practice.

Authors:  Scott E Hadland; John R Knight; Sion K Harris
Journal:  J Dev Behav Pediatr       Date:  2015 Feb-Mar       Impact factor: 2.225

Review 6.  The pharmacologic and clinical effects of medical cannabis.

Authors:  Laura M Borgelt; Kari L Franson; Abraham M Nussbaum; George S Wang
Journal:  Pharmacotherapy       Date:  2013-02       Impact factor: 4.705

7.  Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors.

Authors:  M Ruth Pazos; Nagat Mohammed; Hector Lafuente; Martin Santos; Eva Martínez-Pinilla; Estefania Moreno; Elsa Valdizan; Julián Romero; Angel Pazos; Rafael Franco; Cecilia J Hillard; Francisco J Alvarez; Jose Martínez-Orgado
Journal:  Neuropharmacology       Date:  2013-04-12       Impact factor: 5.250

Review 8.  Medical marijuana and the developing role of the pharmacist.

Authors:  Matthew J Seamon; Jennifer A Fass; Maria Maniscalco-Feichtl; Nada A Abu-Shraie
Journal:  Am J Health Syst Pharm       Date:  2007-05-15       Impact factor: 2.637

9.  In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.

Authors:  T Fisher; H Golan; G Schiby; S PriChen; R Smoum; I Moshe; N Peshes-Yaloz; A Castiel; D Waldman; R Gallily; R Mechoulam; A Toren
Journal:  Curr Oncol       Date:  2016-03-16       Impact factor: 3.677

Review 10.  Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.

Authors:  Pius S Fasinu; Sarah Phillips; Mahmoud A ElSohly; Larry A Walker
Journal:  Pharmacotherapy       Date:  2016-07       Impact factor: 4.705

View more
  10 in total

Review 1.  Gambling and Cannabis Use: Clinical and Policy Implications.

Authors:  Ken C Winters; James P Whelan
Journal:  J Gambl Stud       Date:  2020-03

2.  Epidiolex (Cannabidiol) Primer: Frequently Asked Questions for Patients and Caregivers.

Authors:  Renad Abu-Sawwa; Caitlin Stehling
Journal:  J Pediatr Pharmacol Ther       Date:  2020 Jan-Feb

3.  Is Cannabis Legalization Eliciting Abusive Behaviors in Parents? A Case Report.

Authors:  Marianna Russo; Donata Favretto; Stefano Sartori; Paola Facchin; Melissa Rosa-Rizzotto
Journal:  J Pediatr Pharmacol Ther       Date:  2022-07-06

Review 4.  Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System.

Authors:  Patrícia Schonhofen; Ivi Juliana Bristot; José Alexandre Crippa; Jaime Eduardo Cecílio Hallak; Antônio Waldo Zuardi; Richard B Parsons; Fábio Klamt
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

5.  Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy.

Authors:  James W Wheless; Dennis Dlugos; Ian Miller; D Alexander Oh; Neha Parikh; Steven Phillips; J Ben Renfroe; Colin M Roberts; Isra Saeed; Steven P Sparagana; Jin Yu; Maria Roberta Cilio
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

6.  The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD).

Authors:  Charlotte M Pretzsch; Bogdan Voinescu; Maria A Mendez; Robert Wichers; Laura Ajram; Glynis Ivin; Martin Heasman; Steven Williams; Declan Gm Murphy; Eileen Daly; Gráinne M McAlonan
Journal:  J Psychopharmacol       Date:  2019-06-25       Impact factor: 4.153

7.  Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder.

Authors:  Charlotte Marie Pretzsch; Jan Freyberg; Bogdan Voinescu; David Lythgoe; Jamie Horder; Maria Andreina Mendez; Robert Wichers; Laura Ajram; Glynis Ivin; Martin Heasman; Richard A E Edden; Steven Williams; Declan G M Murphy; Eileen Daly; Gráinne M McAlonan
Journal:  Neuropsychopharmacology       Date:  2019-02-06       Impact factor: 7.853

Review 8.  Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders.

Authors:  Laura D Carreira; Francisca C Matias; Maria G Campos
Journal:  Biomedicines       Date:  2022-03-29

9.  Dronabinol Prescribing and Exposure Among Children and Young Adults Diagnosed with Cancer.

Authors:  Joseph E Rower; Amber D King; Diana Wilkins; Jacob Wilkes; Venkata Yellepeddi; Luke Maese; Richard S Lemons; Jonathan E Constance
Journal:  J Adolesc Young Adult Oncol       Date:  2020-07-14       Impact factor: 2.223

10.  Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial.

Authors:  Daryl Efron; Kaitlyn Taylor; Jonathan M Payne; Jeremy L Freeman; Noel Cranswick; Melissa Mulraney; Chidambaram Prakash; Katherine J Lee; Katrina Williams
Journal:  BMJ Open       Date:  2020-03-08       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.